Search

Your search keyword '"Strassburg C."' showing total 500 results
Start Over Author "Strassburg C."
500 results on '"Strassburg C."'

4. Vergleich von Endobiliärer Photodynamischer Therapie und Endobiliärer Radiofrequenzablation bei Patienten mit Extrahepatischem Cholangiokarzinom unter systemischer Chemotherapie

Author

Möhring, C., additional, Khan, O., additional, Zhou, T., additional, Sadeghlar, F., additional, Mahn, R., additional, Kaczmarek, D. J., additional, Dold, L., additional, Toma, M., additional, Marinova, M., additional, Glowka, T., additional, Matthaei, H., additional, Manekeller, S., additional, Kalff, J. C., additional, Strassburg, C. P., additional, Weismüller, T., additional, and Gonzalez-Carmona, M. A., additional

Published
2023
Full Text
View/download PDF

5. Nichtzirrhotische portale Hypertension: Kardio-MRT zeigt Myokardfibrose und -ödem ähnlich wie bei kompensierter Zirrhose

Author

Isaak, A, additional, Chang, J, additional, Mesropyan, N, additional, Kravchenko, D, additional, Endler, C, additional, Bischoff, L, additional, Böhling, N, additional, Pieper, C, additional, Kütting, D, additional, Strassburg, C P, additional, Attenberger, U, additional, Jansen, C, additional, Praktiknjo, M, additional, and Luetkens, J, additional

Published
2023
Full Text
View/download PDF

7. Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

Author

Hecht, J. R., Raman, S. S., Chan, A., Kalinsky, K., Baurain, J. F., Jimenez, M. M., Garcia, M. M., Berger, M. D., Lauer, U. M., Khattak, Adnan, Carrato, A., Zhang, Y., Liu, K., Cha, E., Keegan, A., Bhatta, S., Strassburg, C. P., Roohullah, A., Hecht, J. R., Raman, S. S., Chan, A., Kalinsky, K., Baurain, J. F., Jimenez, M. M., Garcia, M. M., Berger, M. D., Lauer, U. M., Khattak, Adnan, Carrato, A., Zhang, Y., Liu, K., Cha, E., Keegan, A., Bhatta, S., Strassburg, C. P., and Roohullah, A.

Abstract

Background: Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation. T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than either agent alone. Safety/efficacy of the combination was explored in patients with triple negative breast cancer (TNBC) or colorectal cancer (CRC) with liver metastases.ncidence, and secondary endpoints included efficacy and AEs. Methods: In this phase Ib, multicenter, open-label, parallel cohort study of adults with TNBC or CRC with liver metastases, T-VEC (106 then 108 PFU/ml; ≤ 4 ml) was administered into hepatic lesions via image-guided injection every 21 (±3) days. Atezolizumab 1200 mg was given on day 1 and every 21 (±3) days thereafter. Treatment continued until patients experienced dose-limiting toxicity (DLT), had complete response, progressive disease, needed alternative anticancer treatment, or withdrew due to an adverse event (AE). The primary endpoint was DLT incidence, and secondary endpoints included efficacy and AEs. Results: Between 19 March 2018 and 6 November 2020, 11 patients with TNBC were enrolled (safety analysis set: n = 10); between 19 March 2018 and 16 October 2019, 25 patients with CRC were enrolled (safety analysis set: n = 24). For the 5 patients in the TNBC DLT analysis set, no patient had DLT; for the 18 patients in the CRC DLT analysis set, 3 (17%) had DLT, all serious AEs. AEs were reported by 9 (90%) TNBC and 23 (96%) CRC patients, the majority with grade ≥ 3 [TNBC, 7 (70%); CRC, 13 (54%)], and 1 was fatal [CRC, 1 (4%)]. Evidence of efficacy was limited. Overall response rate was 10% (95% confidence interval 0.3-44.5) for TNBC; one (10%) patient had a partial response. For CRC, no patients had a response; 14 (58%) were unassessable. Conclusions: The safety profile reflected known risks with T-VEC including risks of intrahepatic injection; no unexpected safety findings from addition of a

Published
2023

16. Genetische Hyperbilirubinämien

Author

Strassburg, C. P., Burdelski, M., Manns, M. P., Adler, G., editor, Beglinger, C., editor, Manns, M. P., editor, Müller-Lissner, S., editor, and Schmiegel, W., editor

Published
2000
Full Text
View/download PDF

17. Primär biliäre Zirrhose

Author

Strassburg, C. P., Lüttig, B., Manns, M. P., Adler, G., editor, Beglinger, C., editor, Manns, M. P., editor, Müller-Lissner, S., editor, and Schmiegel, W., editor

Published
2000
Full Text
View/download PDF

18. Autoimmunhepatitis

Author

Strassburg, C. P., Obermayer-Straub, P., Manns, M. P., Adler, G., editor, Beglinger, C., editor, Manns, M. P., editor, Müller-Lissner, S., editor, and Schmiegel, W., editor

Published
2000
Full Text
View/download PDF

21. Diagnose der Mukoviszidose (S2)

Author

NÄHRLICH, L., primary, STUHRMANN-SPANGENBERG, M., additional, BARBEN, J., additional, BARGON, J., additional, BLANKENSTEIN, O., additional, BREMER, W., additional, BRUNSMANN, F., additional, BUCHHOLZ, T., additional, ELLEMUNTER, H., additional, FUSCH, C., additional, GEMBRUCH, U., additional, HAMMERMANN, J., additional, JACOBEIT, J., additional, JUNG, A., additional, KEIM, V., additional, KOPP, I., additional, LOFF, S., additional, MAYR, S., additional, PFEIFFER-AULER, S., additional, ROSSI, R., additional, SITTER, H., additional, STERN, M., additional, STRASSBURG, C., additional, and DERICHS, N., additional

Published
2015
Full Text
View/download PDF

27. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib

Author

Hammel P., Kindler H. L., Reni M., Van Cutsem E., MacArulla T., Hall M. J., Park J. O., Hochhauser D., Arnold D., Oh D. -Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E. M., McGuinness D., Cui K. Y., Joo S., Yoo H. K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J. -L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J. -F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J. -P., Tougeron D., Walter T., Ettrich T., Hacker U. T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J. -W., Oh Park J., Wilmink H., Gallego R. A., Ogalla G. D., Velasco A. G., Cabanas E. G., Gomez Martin C., Ponce C. G., Saez B. L., Lopez R., Martin A. M., Pazo R., Pijaume C. P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D. A., Jeffrey Evans T. R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Hammel P., Kindler H.L., Reni M., Van Cutsem E., MacArulla T., Hall M.J., Park J.O., Hochhauser D., Arnold D., Oh D.-Y., Reinacher-Schick A., Tortora G., Algul H., O'Reilly E.M., McGuinness D., Cui K.Y., Joo S., Yoo H.K., Patel N., Golan T., Chantrill L., Goldstein D., Joubert W., Pavlakis N., Tognela A., Van Fraeyenhove F., Van Laethem J.-L., Peeters M., Dhani N., Kavan P., Lemay F., Adenis A., Artru P., Baba-Hamed N., Belletier C., Ben Abdelghani M., Blanc J.-F., Borg C., Coriat R., Deplanque G., Faroux R., Follana P., Guimbaud R., El Hajbi F., Hautefeuille V., Malka D., Metges J.-P., Tougeron D., Walter T., Ettrich T., Hacker U.T., Hennes E., Jacobasch L., Kanzler S., Pession U., Scholz C., Sinn M., Stein A., Strassburg C., Vogel A., Ben-Shahar M., Brenner R., Epelbaum R., Geva R., Gluzman A., Idelevich E., Kolin M., Semenisty V., Shai A., Stemmer S., Yarom N., Celio L., Conte P., Garufi C., Gianni L., Leonardi F., Maiello E., Di Marco M., Milella M., Pinto C., Santini D., Scartozzi M., Vaccaro V., Vasile E., Kim J.-W., Oh Park J., Wilmink H., Gallego R.A., Ogalla G.D., Velasco A.G., Cabanas E.G., Gomez Martin C., Ponce C.G., Saez B.L., Lopez R., Martin A.M., Pazo R., Pijaume C.P., Rodriguez J., Yaya-Tur R., Arora A., Anthoney D.A., Jeffrey Evans T.R., Harrison M., Palmer D., Sarker D., Starling N., Valle J., Wall L., Agajanian R., Bearden J., Bekaii-Saab T., Carter C., Cohen D., Distefano A., Dragovich T., Ejadi S., Ford J., Grabelsky S., Hall M., Hochster H., Hosein P., Javle M., Kindler H., Lacy J., Laheru D., Leong S., Lowery M., Marsh R., Noonan A., Oberstein P., Ocean A., O'Reilly E., Ryan D., Seery T., Subramaniam S., Van Echo D., Wang-Gillam A., Weekes C., Welch S., Institut Català de la Salut, [Hammel P] Department of Digestive Oncology, Hôpital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France. [Kindler HL] Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, USA. [Reni M] Department of Oncology, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy. [Van Cutsem E] Division of Digestive Oncology, University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium. [Macarulla T] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology, Barcelona, Spain. [Hall MJ] Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, USA, Vall d'Hebron Barcelona Hospital Campus, CCA - Cancer Treatment and Quality of Life, and Oncology

Subjects
Male, 0301 basic medicine, Oncology, medicine.medical_treatment, BRCA, pancreatic cancer, Disease, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Piperazines, Germline, Medicaments antineoplàstics, chemistry.chemical_compound, 0302 clinical medicine, Quality of life, Neoplasm Metastasis, neoplasias::neoplasias por localización::neoplasias del sistema digestivo::neoplasias pancreáticas [ENFERMEDADES], ambiente y salud pública::salud pública::medidas epidemiológicas::demografía::estado de salud::calidad de vida [ATENCIÓN DE SALUD], BRCA1 Protein, Neoplasms::Neoplastic Processes::Neoplasm Metastasis [DISEASES], Hematology, Middle Aged, Progression-Free Survival, humanities, 3. Good health, metastatic, health-related quality of life, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Poly(ADP-ribose) Polymerase Inhibitors, Placebo, olaparib, Olaparib, 03 medical and health sciences, Double-Blind Method, Metàstasi, Pancreatic cancer, Internal medicine, Gastrointestinal Tumors, medicine, Humans, Germ-Line Mutation, Aged, BRCA2 Protein, Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Pancreatic Neoplasms [DISEASES], Chemotherapy, Pàncrees - Càncer, business.industry, BRCA mutation, Original Articles, medicine.disease, Pancreatic Neoplasms, Environment and Public Health::Public Health::Epidemiologic Measurements::Demography::Health Status::Quality of Life [HEALTH CARE], 030104 developmental biology, chemistry, neoplasias::procesos neoplásicos::metástasis neoplásica [ENFERMEDADES], Quality of Life, Phthalazines, Neoplasm Recurrence, Local, business
Abstract

Qualitat de vida relacionada amb la salut; Olaparib; Càncer de pàncrees Calidad de vida relacionada con la salud; Olaparib, Cáncer de páncreas Health-related quality of life; Olaparib; Pancreatic cancer Background Patients with metastatic pancreatic cancer often have a detriment in health-related quality of life (HRQoL). In the randomized, double-blind, phase III POLO trial progression-free survival was significantly longer with maintenance olaparib, a poly(ADP-ribose) polymerase inhibitor, than placebo in patients with a germline BRCA1 and/or BRCA2 mutation (gBRCAm) and metastatic pancreatic cancer whose disease had not progressed during first-line platinum-based chemotherapy. The prespecified HRQoL evaluation is reported here. Patients and methods Patients were randomized to receive maintenance olaparib (300 mg b.i.d.; tablets) or placebo. HRQoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30-item module at baseline, every 4 weeks until disease progression, at discontinuation, and 30 days after last dose. Scores ranged from 0 to 100; a ≥10-point change or difference between arms was considered clinically meaningful. Adjusted mean change from baseline was analysed using a mixed model for repeated measures. Time to sustained clinically meaningful deterioration (TSCMD) was analysed using a log-rank test. Results Of 154 randomized patients, 89 of 92 olaparib-arm and 58 of 62 placebo-arm patients were included in HRQoL analyses. The adjusted mean change in Global Health Status (GHS) score from baseline was

Published
2019

28. Multiparametrisches MRT basiertes Mapping der Leber zur nicht-invasiven Bestimmung des Fibrosegrades bei Patienten mit primär sklerosierender Cholangitis.

Author

Mesropyan, N, additional, Kupczyk, P, additional, Dold, L, additional, Weismüller, T, additional, Sprinkart, M, additional, Pieper, C, additional, Kütting, D, additional, Strassburg, C, additional, Isaak, A, additional, Endler, C, additional, Faron, A, additional, Attenberger, U, additional, and Luetkens, J, additional

Published
2021
Full Text
View/download PDF

34. TLR agonists enhance responsiveness of inflammatory innate immune cells in HLA-B*57-positive HIV patients

Author

Dold, L., primary, Zimmer, L., additional, Schwarze-Zander, C., additional, Boesecke, C., additional, Mohr, R., additional, Wasmuth, J.-C., additional, Ommer, K., additional, Gathof, B., additional, Krämer, B., additional, Nattermann, J., additional, Strassburg, C. P., additional, Rockstroh, J. K., additional, Spengler, U., additional, and Langhans, B., additional

Published
2020
Full Text
View/download PDF

38. Dye chromoendoscopy leads to a higher adenoma detection in the duodenum and stomach in patients with familial adenomatous polyposis

Author

Strassburg, C. P., primary, Nattermann, J., primary, Hüneburg, R., additional, Heling, D., additional, Kaczmarek, D. J., additional, van Heteren, P., additional, Olthaus, M., additional, Fimmers, R., additional, Berger, M., additional, Coch, C., additional, Lau, J. F., additional, Kristiansen, G., additional, Weismüller, T. J., additional, Spier, I., additional, and Aretz, S., additional

Published
2020
Full Text
View/download PDF

39. The bacterial bile microbiome and its role in liver diseases

Author

Tyc, O, additional, Jansen, C, additional, Schierwagen, R, additional, Uschner, F, additional, Israelsen, M, additional, Klein, S, additional, Ortiz, C, additional, Strassburg, C, additional, Zeuzem, S, additional, Gu, W, additional, Torres, S, additional, Praktiknjo, M, additional, Kersting, S, additional, Langheinrich, M, additional, Nattermann, J, additional, Servant, F, additional, Arumugam, M, additional, Krag, A, additional, Lelouvier, B, additional, Weismüller, T, additional, and Trebicka, J, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results